12-month Phase 1 data of #OCU410 for #geographicatrophy (GA) showed 60% slower ellipsoid zone loss and 20.2% reduction in GA lesion growth in treated eyes vs untreated eyes. Safety remains favorable with no serious adverse events reported.
Read more: https://t.co/SAoXizc7uG